Protocol Ledger

NCT07283835 · Phase II · RECRUITING

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

Interventional Phase II clinical trial protocol NCT07283835 sponsored by Lepu Biopharma Co in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-12-04 Enrollment: 16 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07283835
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)16 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07283835
Protocol FieldVerified Registry Value
NCT IdentifierNCT07283835
Consolidated Lead SponsorLepu Biopharma Co
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment16 participants (ESTIMATED)
Registered Start Date2025-12-04
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI